



Ezallor™ (rosuvastatin) – New drug approval

- On December 18, 2018, the FDA approved Sun Pharmaceutical's [Ezallor \(rosuvastatin\)](#) capsules, as adjunctive therapy to diet for the treatment of adult patients with hypertriglyceridemia or primary dysbetalipoproteinemia (Type III Hyperlipoproteinemia); and as adjunctive therapy to other lipid-lowering treatments (eg, low-density lipoprotein [LDL] apheresis) or alone if such treatments are unavailable to reduce LDL-cholesterol, total cholesterol, and apolipoprotein B in adult patients with homozygous familial hypercholesterolemia.
 - Ezallor has not been studied in Fredrickson Type I and V dyslipidemias.
- Rosuvastatin is also available generically as a [tablet](#) and approved for the same indications as Ezallor.
- The approval of Ezallor was based upon efficacy studies conducted for rosuvastatin tablets.
- Ezallor is contraindicated in patients with active liver disease, which may include unexplained persistent elevations of hepatic transaminase levels; pregnancy; and lactation.
- Warnings and precautions of Ezallor include skeletal muscle effects, liver enzyme abnormalities, concomitant coumarin anticoagulants, proteinuria and hematuria, and endocrine effects.
- The most common adverse reactions (> 2%) with Ezallor use were headache, myalgia, abdominal pain, asthenia, and nausea.
- The recommended dose of Ezallor in adults is 5 mg to 40 mg orally once daily, with or without food. The usual starting dose is 10 mg to 20 mg once daily.
 - The maximum Ezallor dose of 40 mg should be used only for those patients who have not achieved their LDL-C goal utilizing the 20 mg dose.
- Sun Pharmaceuticals' launch plans for Ezallor are pending. Ezallor will be available as 5 mg, 10 mg, 20 mg, and 40 mg capsules.



OptumRx® specializes in the delivery, clinical management and affordability of prescription medications and consumer health products. We are an Optum® company — a leading provider of integrated health services. Learn more at [optum.com](#).

All Optum® trademarks and logos are owned by Optum, Inc. All other brand or product names are trademarks or registered marks of their respective owners.

This document contains information that is considered proprietary to OptumRx and should not be reproduced without the express written consent of OptumRx.

RxNews® is published by the OptumRx Clinical Services Department.

©2018 Optum, Inc. All rights reserved.